Risk Factors for the Development of Fellow Eye Horseshoe Retinal Tears Following Horseshoe Retinal Tear in the Presenting Eye

Peng, Enoch T. BS
Parvus, Matthew N. MD
Yu, Hannah J. BS
Laswell, Stephen M. BS
Pearce, William A. MD
Fan, Kenneth C. MD
Major, James C. Jr. MD, PhD
Brown, David M. MD
Wykoff, Charles C. MD, PhD
Patel, Sagar B. MD

From the University of Texas Southwestern Medical School, Dallas, Texas (ETP), Retina Consultants of Texas, Houston, Texas (MNP, HJY, SML, WAP, KCF, JCM, DMB, CCW, SBP), and Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas (WAP, KCF, JCM, DMB, CCW, SBP).

Financial disclosures: DMB reports grants or contracts from Adverum, Alderya, Alexion, Alkahest, Alimera, Amgen, Annexon, Apellis, Aura, Bayer, Boston Image Reading Center, Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, Eyepoint, Genentech/Roche, Graybug, Gyroscope, Gemini, John Hopkins, Ionis, Irenix, Iveric, Kodiak, Lowery Medical Research Group, Lumithera, Nanoscope, NEI/NH, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire Pharma, Inc., OIRRC, ONS, Opthea, Opthotech, OPTOS, Oxurion, Oysterpoint, Regeneron, REGENXBIO, Roche, SamChunDang, Samsung, Sandoz, Santen, Senju, Stealth, Unity, Xbrane, and Zeiss; consulting fees from 4DMT, Adverum Biotechnologies Inc., AGTC, Alexion Pharmaceuticals Inc., Annexon Inc., Apellis Pharmaceuticals Inc., Bayer, Biogen MA Inc., Boehringer Ingelheim, Celltrion Inc., Chengdu Kanghong Pharmaceutical, Clearside Biomedical Inc., Coherus BioScience Inc., Gemini Therapeutics Inc., Glaukos, Heidelberg Engineering Inc., Iveric Bio Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Medscape LLC, Molecular Partners AG, Novartis Pharma AG, Ocular Therapeutix, Ocuphire Pharma Inc., OPTOS PLC, PPD, Regeneron Pharmaceuticals Inc., RetinAI Medical AG, Ray Therapeutics Inc., Samsung Bioepis Co. Ltd., Senju Pharmaceuticals Co.Ltd., SciNeuro Therapeutics Inc., Smilebiotek Zhuhai Limited, Stealth BioTherapeutics Inc., Verseon, and WebMD Global LLC; payments or honoraria from 4DMT, Adverum Biotechnologies Inc., AGTC, Alexion Pharmaceuticals Inc., Annexon Inc., Apellis Pharmaceuticals Inc., Bayer, Biogen MA Inc., Boehringer Ingelheim, Celltrion Inc., Chengdu Kanghong Pharmaceutical, Clearside Biomedical Inc., Coherus BioScience Inc., Gemini Therapeutics Inc., Glaukos, Heidelberg Engineering Inc., Iveric Bio Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Medscape LLC, Molecular Partners AG, Novartis Pharma AG, Ocular Therapeutix, Ocuphire Pharma Inc., OPTOS PLC, PPD, Regeneron Pharmaceuticals Inc., RetinAI Medical AG, Ray Therapeutics Inc., Samsung Bioepis Co. Ltd., Senju Pharmaceuticals Co.Ltd., SciNeuro Therapeutics Inc., Smilebiotek Zhuhai Limited, Stealth BioTherapeutics Inc., Verseon, and WebMD Global LLC; and has a patent for OPTOS camera software used to dewarp images. CCW reports grants or contracts paid to CCW's institution by 4DMT, Adverum, AffaMed, Alexion, Alimera, Alkahest, Allgenesis, Amgen, Annexin, Annexon, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Chengdu, Kanghong, Clearside, Curacle, EyePoint, Gemini, Genentech, GlaxoSmithKline, Gyroscope, IONIS, iRENIX, IVERIC bio, Kodiak, LMRI, Nanoscope, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, Ophthotech, Opthea, Oxurion, Oxular, Oyster Point, PerceiveBio, Regeneron, RegenXBio, Roche, SamChunDang Pharm, Sandoz, Senju, UNITY, Verily, and Xbrane; consulting fees from 4DMT, AbbVie, Adverum, Aerie, AGTC, Alcon, Annexon, Apellis, Arrowhead, Bausch + Lomb, Boehringer Ingelheim, Cholgene, Clearside, Curacle, EyePoint, Foresite, Frontera, Genentech, Gyroscope, IACTA, IVERIC Bio, Janssen, Kato, Kiora, Kodiak, Kriya, Merck, Nanoscope, NGM, Notal Vision, Novartis, Ocular Therapeutix, Ocuterra, ONL, Opthea, Oxular, Palatin, PerceiveBio, Perfuse, Ray, RecensMedical, Regeneron, RegenXBio, Resonance, Roche, SciNeuro, Stealth, Surrozen, THEA, TissueGen, Valo, and Vitranu; payments from Kato and Aerie for participation on a data safety monitoring board or advisory board; is a board member for ASRS and the Vit-Buckle Society; and has stock options in ONL, PolyPhotonix, Recens-Medical, TissueGen, Visgenx, and Vitranu. The remaining authors have no relevant financial relationships to disclose.

Address correspondence to Charles C. Wykoff, MD, PhD, Retina Consultants of Texas, 4460 Bissonnet Street, Suite 200, Bellaire, TX 77401; email: [email protected].

Received October 07, 2022

Accepted March 23, 2023

Ophthalmic Surgery, Lasers, and Imaging Retina 54(6):p 338-345, June 01, 2023. | DOI: 10.3928/23258160-20230523-01

Background:

This study investigated factors associated with fellow eye horseshoe retinal tear (HST) development in consecutive patients with a presenting eye HST.

Materials and Methods:

Medical records were reviewed for patients with initial HSTs between 2015 and 2017 and 24 factors were analyzed. Logistic regression was used to assess factors associated with fellow eye HST development.

Results:

In total, 242 patients with an HST were identified with mean follow-up of 68.3 months. Four associations with fellow eye HST development were identified: (1) presence of fellow eye lattice degeneration, (2) subsequent presenting eye HSTs, (3) fellow eye vitreous hemorrhage at presenting eye HST occurrence, (4) OCT-determined stage 3 fellow eye posterior vitreous detachment at presenting eye HST occurrence.

Conclusion:

Four clinical findings associated with fellow eye HST development following presenting eye HST were identified. These factors may be important considerations during management patients with HST.

[Ophthalmic Surg Lasers Imaging Retina 2023;54:338–345.]